SSY Group Limited (02005.HK): Obtains Drug Production Registration Approval for Doxapram Hydrochloride Injection, First Approved in China
NewTimeSpace: SSY Group Limited (02005.HK) announced a voluntary announcement that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the National Medical Products Administration (NMPA) of China.The product is classified as a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first approval among domestic enterprises, mainly indicated for the treatment of respiratory failure.
NewTimeSpace : SSY Group Limited (02005.HK) issued a voluntary announcement on March 3, 2026, stating that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the NMPA.
The product is a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first product of its kind approved by a domestic enterprise, and is mainly used for the treatment of respiratory failure.
Tags：
- SSY GROUP (02005.HK): Gadobutrol API Approved for Registration by NMPA, a New-Generation Macrocyclic MRI Contrast Agent
- SSY GROUP (02005.HK): Choline Fenofibrate Sustained-release Capsule Obtains Drug Production Registration Approval
- SSY GROUP (02005.HK): Baloxavir Marboxil API Approved for Registration, Becoming the Third Domestic Enterprise with Such Approval
- SSY GROUP (02005.HK): Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection Obtain Drug Registration Approvals, Deemed to Have Passed Consistency Evaluation
- SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
